September 25, 2024
In the past three months, 7 analysts have released ratings for ResMed (NYSE:RMD), presenting a wide array of perspectives from bullish to bearish. This diverse set of opinions indicates that the analysts have varying views on the company's potential performance in the future.
According to a recent report, the total ratings can be broken down into the following categories: Bullish - 1, Somewhat Bullish - 2, Indifferent - 3, Somewhat Bearish - 1, and Bearish - 0. In the last 30 days, there have been no changes to the ratings, with the same numbers as the previous month.
However, in the 1-month-ago period, the ratings were different, with 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 1 Somewhat Bearish, and 2 Bearish ratings. In the 2-month-ago period, the breakdown was 1 Bullish, 1 Somewhat Bullish, 1 Indifferent, 0 Somewhat Bearish, and 3 Bearish ratings. Lastly, in the 3-month-ago period, there were 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 1 Somewhat Bearish, and 0 Bearish ratings.
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $227.57, accompanied by a high estimate of $280.00 and a low estimate of $180.00. Witnessing a positive shift, the current average has risen by 3.68% from the previous average price target of $219.50.
The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joe Vruwink | Baird | Announces | Outperform | $280.00 | - |
| Mike Polark | Wolfe Research | Announces | Underperform | $180.00 | - |
| Mike Matson | Needham | Maintains | Hold | $236.00 | - |
| Craig Wong-Pan | RBC Capital | Raises | Sector Perform | $206.00 | $204.00 |
| Brett Fishbin | Keybanc | Raises | Overweight | $251.00 | $238.00 |
| Mike Matson | Needham | Maintains | Buy | $236.00 | $236.00 |
| Craig Wong-Pan | RBC Capital | Raises | Sector Perform | $204.00 | $200.00 |
Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. This gives a clear view into the expected performance of ResMed in the future, enabling investors to make informed decisions.
October 16, 2024
World Spine Day, observed on October 16th, serves as a potent reminder of the importance of maintaining a healthy spine. As the backbone of our bod...
September 24, 2024
Liberty Tax Inc (OTCMKTS:TAXA) shares witnessed a significant surge during trading on Monday as the stock crossed above its 200-day moving average....
October 4, 2024
Disney star Halle Bailey and rapper DDG have left their fans stunned with the news of their surprise break-up. The young couple has decided to go t...
January 15, 2025
LOS ANGELES — The downtown sky was back to its usual clear blue Monday, free from the smoke, haze and ash that had blanketed many corners of Los An...
December 22, 2024
Tank Dell, the Texans' talented young wide receiver, was carted off the field in Saturday's game against the Chiefs after suffering a gruesome leg ...